Journal article

Prognostic gene expression signature for high-grade serous ovarian cancer

J Millstein, T Budden, EL Goode, MS Anglesio, A Talhouk, MP Intermaggio, HS Leong, S Chen, W Elatre, B Gilks, T Nazeran, M Volchek, RC Bentley, C Wang, DS Chiu, S Kommoss, SCY Leung, J Senz, A Lum, V Chow Show all

ANNALS OF ONCOLOGY | ELSEVIER | Published : 2020

Abstract

BACKGROUND: Median overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ∼4 years, yet survival varies widely between patients. There are no well-established, gene expression signatures associated with prognosis. The aim of this study was to develop a robust prognostic signature for OS in patients with HGSOC. PATIENTS AND METHODS: Expression of 513 genes, selected from a meta-analysis of 1455 tumours and other candidates, was measured using NanoString technology from formalin-fixed paraffin-embedded tumour tissue collected from 3769 women with HGSOC from multiple studies. Elastic net regularization for survival analysis was applied to develop a prognostic model for..

View full abstract

Grants

Awarded by National Institutes of Health/National Cancer Institute (NCI)


Awarded by United States Department of Defense Ovarian Cancer Research Program


Awarded by National Institutes of Health/National Cancer Institute


Awarded by Career Enhancement Awardee of the Mayo Clinic SPORE in Ovarian Cancer


Awarded by Cancer Australia


Awarded by European Union's Horizon 2020 European Research Council Programme


Awarded by American Cancer Society Early Detection Professorship


Awarded by National Center for Advancing Translational Sciences (NCATS)


Awarded by Canadian Institutes of Health Research


Awarded by National Health and Medical Research Council Enabling


Awarded by Cancer Institute NSW


Awarded by U.S. Army Medical Research and Materiel Command


Awarded by Cancer Foundation of Western Australia


Awarded by National Health and Medical Research Council of Australia


Awarded by Ovarian Cancer Action


Awarded by Cancer Research UK


Awarded by Department of Defense Award


Awarded by National Institute for Health Research University College London Hospitals Biomedical Research Centre


Awarded by MRC


Funding Acknowledgements

This work was funded by the National Institutes of Health/National Cancer Institute (NCI) Grants to SJR [grant number R01CA172404] and J.A. Doherty and MAR [grant number R01CA168758], the Canadian Institutes for Health Research (Proof-of-Principle I program, no grant number applicable) and the United States Department of Defense Ovarian Cancer Research Program [grant number OC110433]. J. Millstein and SJR received support from National Institutes of Health/National Cancer Institute [grant number P30CA014089] and J. Millstein received support from NIH/National Cancer Institute award number P01CA196569. MSA receives funding from the Janet D. Cottrelle Foundation Scholar's program managed by the BC Cancer Foundation (no grant number applicable). JG was partially supported by the National Institutes of Health/National Cancer Institute [grant number P30CA034196]. CW was a Career Enhancement Awardee of the Mayo Clinic SPORE in Ovarian Cancer [grant number P50 CA136393]. MJH received funding from Cancer Australia (1067110), DGH receives support from the Dr Chew Wei Memorial Professorship in Gynecologic Oncology, (no grant number applicable) the Canada Research Chairs program (Research Chair in Molecular and Genomic Pathology, no grant number applicable), and the Janet D. Cottrelle Foundation (no grant number applicable). MW receives funding from the European Union's Horizon 2020 European Research Council Programme [grant number H2020 BRCA-ERC] under Grant Agreement No. 742432, as well as from the charity The Eve Appeal (https://eveappeal.org.uk/, no grant number applicable) and support from the National Institute for Health Research (NIHR, no grant number applicable) and the University College London Hospitals (UCLH) Biomedical Research Centre (no grant number applicable). GEK is supported by the Miriam and Sheldon Adelson Medical Research Foundation (no grant number applicable). BYK is funded by the American Cancer Society Early Detection Professorship [grant number SIOP-06-258-01-COUN] and the National Center for Advancing Translational Sciences (NCATS) [grant number UL1TR000124]. HRH is supported by the National Institutes of Health/National Cancer Institute [grant number K22 CA193860]. OVCARE (including the VAN study) receives core funding through the BC Cancer Foundation (no grant number applicable) and The VGH+UBC Hospital Foundation (authors AT, BG, DGH and MSA, no grant number applicable). The AOV study is supported by the Canadian Institutes of Health Research [grant number MOP-86727]. The Gynaecological Oncology Biobank at Westmead, a member of the Australasian Biospecimen Network-Oncology group, was funded by the National Health and Medical Research Council Enabling [grant numbers ID 310670, ID 628903] and the Cancer Institute NSW [grant numbers ID 12/RIG/1-17, 15/RIG/1-16]. The Australian Ovarian Cancer Study Group was supported by the U.S. Army Medical Research and Materiel Command [grant number DAMD17-01-1-0729], The Cancer Council Victoria, Queensland Cancer Fund, The Cancer Council New South Wales, The Cancer Council South Australia, The Cancer Council Tasmania and The Cancer Foundation of Western Australia (Multi-State Applications 191, 211 and 182) and the National Health and Medical Research Council of Australia [grant numbers NHMRC, ID199600, ID400413, ID400281].BriTROC-1 was funded by Ovarian Cancer Action (to IAM and JDB) [grant number 006] and supported by Cancer Research UK [grant numbers A15973, A15601, A18072, A17197, A19274, A19694] and the National Institute for Health Research Cambridge and Imperial Biomedical Research Centres (no grant number applicable). SEARCH was supported by Cancer Research UK [grant number A16561]. The University of Cambridge receives salary support for PDPP from the NHS Clinical Academic Reserve (no grant number applicable). Samples from the Mayo Clinic were collected and provided with support of the National Institutes of Health/National Cancer Institute (NCI) P50 CA136393 (ELG, GLK, SHK, MES). S. Orsulic was funded by the Department of Defense Award W81XWH-17-1-0144. MRC Clinical Trials Unit at UCL receives funding from The Eve Appeal (The Oak Foundation) with investigators supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre and MRC core funding (MR_UU_12023).